FDA Approval: First Probuphine Implant for Opioid Dependence

Share this content:
This new form of treatment is designed to last 6 months.
This new form of treatment is designed to last 6 months.

HealthDay News — The US Food and Drug Administration has approved the first-ever buprenorphine implant to treat opioid dependence, the agency said Thursday in a news release.

Up to now, the drug buprenorphine has only been available in pill or film form to be placed under a person's tongue, the FDA said. Probuphine, which provides a constant, low-level dose of the drug, is designed to last 6 months. The drug, combined with behavioral therapy, can combat opioid addiction without "causing the cycle of highs and lows associated with opioid misuse or abuse," and can make the addictive qualities of opioid use less attractive, the FDA said. The agency cited US government statistics that opioid addicts receiving this combined therapy cut their risk of death from all causes by half.


Probuphine's 4 one-inch rods are surgically implanted under the skin of the upper arm. If additional treatment is needed, a second set of rods may subsequently be implanted in the opposite arm. Sixty-three percent of people who used Probuphine had no evidence of illicit opioid use throughout the 6 months of treatment, the agency said.

The label includes a boxed warning of potential dangers during the product's insertion or removal, the FDA said. These include the potential risks of implant protrusion and nerve damage.

Probuphine is marketed by San Francisco-based Titan Pharmaceuticals and Princeton, NJ-based Braeburn Pharmaceuticals.

More information at the FDA news release.

You must be a registered member of Neurology Advisor to post a comment.

Sign Up for Free e-newsletters

CME Focus